In the last trading session, 1.4 million shares of the Compass Therapeutics Inc (NASDAQ:CMPX) were traded, and its beta was 0.76. Most recently the company’s share price was $2.60, and it changed around $0.1 or 4.00% from the last close, which brings the market valuation of the company to $357.73M. CMPX currently trades at a discount to its 52-week high of $2.70, offering almost -3.85% off that amount. The share price’s 52-week low was $0.76, which indicates that the current value has risen by an impressive 70.77% since then. We note from Compass Therapeutics Inc’s average daily trading volume that its 10-day average is 4.0 million shares, with the 3-month average coming to 1.03 million.
Compass Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.38. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended CMPX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Compass Therapeutics Inc is expected to report earnings per share of -0.09 for the current quarter.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Instantly CMPX has showed a green trend with a performance of 4.00% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.70 on recent trading dayincreased the stock’s daily price by 3.7%. The company’s shares are currently up 79.31% year-to-date, but still up 46.89% over the last five days. On the other hand, Compass Therapeutics Inc (NASDAQ:CMPX) is 74.50% up in the 30-day period. We can see from the shorts that 2.21 million shares have been sold at a short interest cover period of 5.85 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 48.0% from its current value. Analyst projections state that CMPX is forecast to be at a low of $5 and a high of $5.
Compass Therapeutics Inc (CMPX) estimates and forecasts
Compass Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 170.83 percent over the past six months and at a -6.06% annual growth rate that is well below the industry average of 16.50%.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 12.88%.
CMPX Dividends
Compass Therapeutics Inc’s next quarterly earnings report is expected to be released in February.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 12.51% of Compass Therapeutics Inc shares, and 73.50% of them are in the hands of institutional investors. The stock currently has a share float of 84.01%. Compass Therapeutics Inc stock is held by 111.0 institutions, with ORBIMED ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 16.3701% of the shares, which is about 22.36 million shares worth $22.36 million.
ADAGE CAPITAL PARTNERS GP, L.L.C., with 8.1474% or 11.13 million shares worth $11.13 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Oct 31, 2024 . The former held 2.52 shares worth $6.54 million, making up 4.83% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.19 shares worth around $5.7 million, which represents about 4.20% of the total shares outstanding.
